Last reviewed · How we verify
CD07805/47 gel 0.5%/CD07805/47 Vehicle
CD07805/47 gel 0.5%/CD07805/47 Vehicle is a Retinoid Small molecule drug developed by Galderma R&D. It is currently in Phase 3 development for Acne vulgaris, Photoaging/photodamaged skin. Also known as: brimonidine tartrate gel 0.5%, brimonidine tartrate gel vehicle.
CD07805/47 is a topical retinoid that modulates retinoid receptor signaling to reduce inflammation and promote skin cell differentiation in dermatological conditions.
CD07805/47 is a topical retinoid that modulates retinoid receptor signaling to reduce inflammation and promote skin cell differentiation in dermatological conditions. Used for Acne vulgaris, Photoaging/photodamaged skin.
At a glance
| Generic name | CD07805/47 gel 0.5%/CD07805/47 Vehicle |
|---|---|
| Also known as | brimonidine tartrate gel 0.5%, brimonidine tartrate gel vehicle |
| Sponsor | Galderma R&D |
| Drug class | Retinoid |
| Target | Retinoid receptors (RAR/RXR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
CD07805/47 is a selective retinoid compound designed for topical application. It binds to retinoid receptors in the skin, promoting keratinocyte differentiation and reducing inflammatory responses. The gel formulation is optimized for dermal penetration while the vehicle control allows for efficacy comparison in clinical trials.
Approved indications
- Acne vulgaris
- Photoaging/photodamaged skin
Common side effects
- Skin irritation
- Erythema
- Dryness
- Peeling
Key clinical trials
- Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea (PHASE3)
- Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea (PHASE2)
- Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD07805/47 gel 0.5%/CD07805/47 Vehicle CI brief — competitive landscape report
- CD07805/47 gel 0.5%/CD07805/47 Vehicle updates RSS · CI watch RSS
- Galderma R&D portfolio CI
Frequently asked questions about CD07805/47 gel 0.5%/CD07805/47 Vehicle
What is CD07805/47 gel 0.5%/CD07805/47 Vehicle?
How does CD07805/47 gel 0.5%/CD07805/47 Vehicle work?
What is CD07805/47 gel 0.5%/CD07805/47 Vehicle used for?
Who makes CD07805/47 gel 0.5%/CD07805/47 Vehicle?
Is CD07805/47 gel 0.5%/CD07805/47 Vehicle also known as anything else?
What drug class is CD07805/47 gel 0.5%/CD07805/47 Vehicle in?
What development phase is CD07805/47 gel 0.5%/CD07805/47 Vehicle in?
What are the side effects of CD07805/47 gel 0.5%/CD07805/47 Vehicle?
What does CD07805/47 gel 0.5%/CD07805/47 Vehicle target?
Related
- Drug class: All Retinoid drugs
- Target: All drugs targeting Retinoid receptors (RAR/RXR)
- Manufacturer: Galderma R&D — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Acne vulgaris
- Indication: Drugs for Photoaging/photodamaged skin
- Also known as: brimonidine tartrate gel 0.5%, brimonidine tartrate gel vehicle
- Compare: CD07805/47 gel 0.5%/CD07805/47 Vehicle vs similar drugs
- Pricing: CD07805/47 gel 0.5%/CD07805/47 Vehicle cost, discount & access